| Literature DB >> 28670644 |
Solayide A Adesida1, Cynthia C Ezenta1, Ajoke O Adagbada2, Amudat A Aladesokan3, Akitoye O Coker4.
Abstract
BACKGROUND: Enterococci are indigenous flora of the gastro-intestinal tracts of animals and humans. Recently, interest in two major species, E. faecium and E. faecalis, has heightened because of their ability to cause serious infections and their intrinsic resistance to antimicrobials. This study was aimed at determining the prevalence of E. faecium and E. faecalis in human faecal samples and evaluating the susceptibility of the isolates to antibiotics.Entities:
Keywords: Antibiotic resistance; Biochemical identification; Enterococcus faecalis; Enterococcus faecium; Human faecal samples
Year: 2017 PMID: 28670644 PMCID: PMC5476817 DOI: 10.21010/ajid.v11i2.11
Source DB: PubMed Journal: Afr J Infect Dis ISSN: 2006-0165
Sugar Utilisation Reaction of Enterococcus faecalis and Enterococcus faecium
| No of Positive Isolates (%) | ||
|---|---|---|
| 0 (0%) | 36 (100%) | |
| 29 (100%) | 0 (0%) | |
| 29 (100%) | 36 (100%) | |
| 29 (100%) | 36 (100%) | |
| 29 (100%) | 36 (100%) | |
| 29 (100%) | 36 (100%) | |
| 29 (100%) | 36 (100%) | |
| 29 (100%) | 36 (100%) | |
| 29 (100%) | 36 (100%) | |
| 0 (0%) | 0 (0%) | |
| 29 (100%) | 36 (100%) | |
| 0 (0%) | 0 (0%) | |
Gender-wise Distribution of Enterococcus faecium and Enterococcus faecalis
| Sex | No of Samples Collected | No of Enterococci Isolated | No of : | |
|---|---|---|---|---|
| Male | 50 | 38 | 16 | 15 |
| Female | 50 | 35 | 20 | 14 |
| Total | 100 | 73 | 36 | 29 |
Antimicrobial susceptibility of Enterococcus Isolates to antimicrobial agents
| Antibiotics | Total | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Vancomycin | 25(86.2) | 1(3.5) | 3(10.4) | 30(83.3) | - | 6(16.7) | 55(84.6) | 1(1.5) | 9(13.8) |
| Teicoplanin | 18(62.1) | - | 11(37.9) | 29(80.6) | - | 7(19.4) | 47(72.3) | - | 18(27.7) |
| Amoxicillin-clavulanate | 10(34.5) | 1(3.5) | 18(62.1) | 9(25.0) | 4(11.1) | 23(63.9) | 19(29.2) | 5(7.7) | 41(63.1) |
| Ofloxacin | 13(44.8) | 3(10.4) | 13(44.8) | 17(47.2) | 3(8.3) | 16(44.4) | 30(46.2) | 6(9.2) | 29(44.6) |
| Erythromycin | 1(3.5) | - | 28(96.6) | 1(2.8) | 3(8.3) | 32(88.9) | 2(3.1) | 3(4.6) | 60(92.3) |
| Gentamicin | 1(3.5) | - | 28(96.6) | 8(22.2) | - | 28(77.8) | 9(13.8) | - | 56(86.2) |
| Ceftriaxone | - | - | 29(100) | - | - | 36(100) | - | - | 65(100) |
| Cefuroxine | - | - | 29(100) | - | - | 36(100) | - | - | 65(100) |
| Ceftizoxime | - | - | 29(100) | - | - | 36(100) | - | - | 65(100) |
Abbreviation: S= Susceptible, I= Intermediate, R= Resistant
Figure 1Antimicrobial resistance rates of Enterococcus faecalis and Enterococcus faecium isolates from Apparently Healthy Humans. Abbreviations: VAN-Vancomycin; TEC-Teicoplanin; AMC - Amoxicillin-clavulanate; OFL- Ofloxacin; ERY-Erythromycin; GEN-Gentamicin; CRO - Ceftriaxone; CXM - Cefuroxime; ZOX- Ceftizoxime.
Resistance Rate of the Isolates to Classes of Antimicrobials Tested
| Classes of Antimicrobials | Antimicrobial agent | Species | No. of resistant isolates (%) |
|---|---|---|---|
| Glycopeptide | Vancomycin | 6 (16.67) | |
| 3 (10.34) | |||
| Teicoplanin | 7 (19.44) | ||
| 11 (37.9) | |||
| Beta-lactam inhibitor | Amoxicillin-clavulanate | 23 (63.9) | |
| 18 (62.1) | |||
| Fluoroquinolone | Ofloxacin | 16 (44.4) | |
| 13 (44.8) | |||
| Macrolide | Erythromycin | 32 (88.9) | |
| 28 (96.6) | |||
| Aminoglycoside | Gentamicin | 28 (77.8) | |
| 28 (96.6) | |||
| 36 (100) | |||
| Cephalosporins | Ceftriaxone | 29 (100) | |
| Cefuroxime | 36 (100) | ||
| 29 (100) | |||
| Ceftizoxime | 36 (100) | ||
| 29 (100) |